Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma.
early stage
endometrial carcinoma
microsatellite instability
mismatch repair protein
myoinvasive pattern
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Nov 2019
22 Nov 2019
Historique:
received:
30
09
2019
revised:
07
11
2019
accepted:
20
11
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
epublish
Résumé
Low-grade and early Federation for Gynecology and Obstetrics (FIGO) stage endometrioid endometrial carcinomas (EEC) have an excellent prognosis. However, approximately 10% of patients develop recurrence, which cannot be correctly predicted at diagnosis. We evaluated myoinvasive patterns as a prognostic factor of relapse in low-grade, early-stage EEC. Two-hundred and fifty-eight cases were selected according to the following inclusion criteria: (i) endometrioid endometrial carcinomas, (ii) grade 1 or 2 with (iii) FIGO stage I or II, and (iv) clinical follow-up. Slides were reviewed to annotate the myoinvasive pattern present in each case (infiltrative glands, microcystic, elongated and fragmented -MELF-, broad front, adenomyosis-like and adenoma malignum). Microsatellite instability was studied by immunoexpression of mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6). There were 29 recurrences (11.2%) among the 258 cases analysed. A predominant broad front myoinvasive pattern was significantly associated with tumour relapse (
Identifiants
pubmed: 31766622
pii: cancers11121845
doi: 10.3390/cancers11121845
pmc: PMC6966575
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III, European Development Regional Fund 'A way to achieve Europe' (FEDER)
ID : PI17/01723
Références
Pathol Oncol Res. 2019 Jan;25(1):123-130
pubmed: 28990139
Mod Pathol. 2016 Jan;29 Suppl 1:S59-77
pubmed: 26715174
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Histopathology. 2011 May;58(6):966-73
pubmed: 21438907
Cancers (Basel). 2018 Oct 30;10(11):null
pubmed: 30380719
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 2007 May 20;25(15):2042-8
pubmed: 17513808
Gynecol Oncol. 2006 Jun;101(3):520-9
pubmed: 16556457
Adv Anat Pathol. 2013 May;20(3):141-7
pubmed: 23574770
Gynecol Oncol. 2017 Jan;144(1):107-112
pubmed: 27789083
Am J Surg Pathol. 2017 Jan;41(1):49-55
pubmed: 27740968
Cancers (Basel). 2018 Aug 21;10(9):null
pubmed: 30134578
J Obstet Gynaecol. 2015 May;35(4):397-402
pubmed: 25279582
Histopathology. 2014 Feb;64(3):389-98
pubmed: 24215212
Int J Gynecol Pathol. 2014 Mar;33(2):127-34
pubmed: 24487466
Int J Gynecol Pathol. 2018 Jan;37(1):17-21
pubmed: 28319574
Int J Gynecol Pathol. 2012 Jul;31(4):337-43
pubmed: 22653347
Am J Surg Pathol. 2013 Nov;37(11):1728-36
pubmed: 24061515
Pathol Int. 2003 Aug;53(8):495-500
pubmed: 12895227
Gynecol Oncol. 2017 Apr;145(1):200-207
pubmed: 28040204
Int J Gynecol Pathol. 2003 Oct;22(4):324-33
pubmed: 14501811
Hum Pathol. 2017 Apr;62:33-39
pubmed: 27864117
Mod Pathol. 2003 Nov;16(11):1148-58
pubmed: 14614055
Obstet Gynecol. 2010 Nov;116(5):1141-9
pubmed: 20966700
Br J Cancer. 2015 Mar 3;112(5):793-801
pubmed: 25675149
Hum Pathol. 2008 Jan;39(1):116-25
pubmed: 17949789
Am J Surg Pathol. 2017 Jul;41(7):896-905
pubmed: 28418994
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Pathology. 2009;41(5):454-9
pubmed: 19900084
J Clin Oncol. 2016 Sep 1;34(25):3062-8
pubmed: 27325856
Int J Gynecol Pathol. 2009 Jan;28(1):1-9
pubmed: 19047915
Eur J Cancer. 2016 Dec;69:51-60
pubmed: 27816832
Gynecol Oncol. 2014 Jul;134(1):20-3
pubmed: 24814467
J Clin Oncol. 2001 Feb 15;19(4):1008-14
pubmed: 11181663
Histopathology. 2019 Dec;75(6):813-824
pubmed: 31310679